|
| |
| | | | 1 | | | DO1.PCCNTR.1194626 ContractData Container |
| | | 1.1 | | | | | | | | | | 129,860.00 | 0.00 | 0.00 | 0.00 | 129,520.00 | 129,860.00 |
|
| | | | | | | 1 | | 2.3.4.1.01 | Atenolol 50 mg, 100/1 | 9 | CAJ | 300 | 350 | 3,150.00 | | 0.00 | | | 0.00 | | 0.00 | 2,700.00 | 3,150.00 | |
|
| | | | | | | 2 | | 2.3.4.1.01 | Diclofenac 75mg/3ml, 100/1 | 6 | CAJ | 1,100 | 1,500 | 9,000.00 | | 0.00 | | | 0.00 | | 0.00 | 6,600.00 | 9,000.00 | |
|
| | | | | | | 3 | | 51161620 - Difenhidramina |
| 2.3.4.1.01 | Difennhidramina Ampolla x 1ml, 100/1 | 5 | CAJ | 7,800 | 7,500 | 37,500.00 | | 0.00 | | | 0.00 | | 0.00 | 39,000.00 | 37,500.00 | |
|
| | | | | | | 4 | | 51151749 - Dextroanfetami(...)51151749 - Dextroanfetamina |
| 2.3.4.1.01 | Dexametasona Amp. 8mg/2ml, 10/1 | 5 | CAJ | 1,000 | 1,118 | 5,590.00 | | 0.00 | | | 0.00 | | 0.00 | 5,000.00 | 5,590.00 | |
|
| | | | | | | 5 | | 2.3.4.1.01 | Atropina Ampolla x 1ml, 100/1 | 5 | CAJ | 7,800 | 6,600 | 33,000.00 | | 0.00 | | | 0.00 | | 0.00 | 39,000.00 | 33,000.00 | |
|
| | | | | | | 6 | | 2.3.4.1.01 | Acetaminofen capsula 500mg, 100/1 | 8 | CAJ | 400 | 420 | 3,360.00 | | 0.00 | | | 0.00 | | 0.00 | 3,200.00 | 3,360.00 | |
|
| | | | | | | 7 | | 2.3.4.1.01 | Complejo B Ampolla 10ml, 10/1 | 6 | CAJ | 1,000 | 990 | 5,940.00 | | 0.00 | | | 0.00 | | 0.00 | 6,000.00 | 5,940.00 | |
|
| | | | | | | 8 | | 51161620 - Difenhidramina |
| 2.3.4.1.01 | Furosemida Ampolla 20mg 2ml, 100/1 | 5 | CAJ | 1,000 | 1,800 | 9,000.00 | | 0.00 | | | 0.00 | | 0.00 | 5,000.00 | 9,000.00 | |
|
| | | | | | | 9 | | 2.3.4.1.01 | Captopril 50mg 10x10 tabletas, 100/1 | 6 | CAJ | 810 | 810 | 4,860.00 | | 0.00 | | | 0.00 | | 0.00 | 4,860.00 | 4,860.00 | |
|
| | | | | | | 10 | | 2.3.4.1.01 | Amoxicilina capsula 500mg, 100/1 | 8 | CAJ | 695 | 695 | 5,560.00 | | 0.00 | | | 0.00 | | 0.00 | 5,560.00 | 5,560.00 | |
|
| | | | | | | 11 | | 51161620 - Difenhidramina |
| 2.3.4.1.01 | Sertal Compuesto Ampolla 3/1 | 6 | CAJ | 2,100 | 2,150 | 12,900.00 | | 0.00 | | | 0.00 | | 0.00 | 12,600.00 | 12,900.00 | |
|
|
| | | |
| | | |
|